Orbimed Advisors LLC Corvus Pharmaceuticals, Inc. Transaction History
Orbimed Advisors LLC
- $4.24 Billion
- Q3 2024
A detailed history of Orbimed Advisors LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,943,654 shares of CRVS stock, worth $33.3 Million. This represents 0.86% of its overall portfolio holdings.
Number of Shares
6,943,654
Previous 6,943,654
-0.0%
Holding current value
$33.3 Million
Previous $12.6 Million
190.12%
% of portfolio
0.86%
Previous 0.3%
Shares
6 transactions
Others Institutions Holding CRVS
# of Institutions
73Shares Held
30.4MCall Options Held
1.06MPut Options Held
84.3K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$26.7 Million0.08% of portfolio
-
Samlyn Capital, LLC New York, NY4.53MShares$21.7 Million0.39% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$15.7 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$11.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.5MShares$7.19 Million1.16% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $223M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...